• Profile
Close

Cancer immunotherapy in patients with preexisting rheumatologic disease: The Mayo Clinic experience

Arthritis & Rheumatism Jan 29, 2018

Richter MD, et al. - Authors pursued this research in order to gauge the risk of rheumatologic disease flare and adverse effects in patients with preexisting rheumatologic disease receiving checkpoint inhibitor therapy. No substantial variations were brought to light with regard to time from cancer diagnosis to immunotherapy, duration of immunotherapy, age, or sex between the patients with and without Immune-related adverse effects (IRAEs). It was discovered that only a minority of the patients experienced a flare of their preexisting rheumatologic disease or any other IRAE.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay